BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 15853698)

  • 1. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced torsade de pointes: from molecular biology to bedside.
    Tamargo J
    Jpn J Pharmacol; 2000 May; 83(1):1-19. PubMed ID: 10887935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of drug induced QT interval prolongation.
    Ponte ML; Keller GA; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT interval prolongation and cardiac risk assessment for novel drugs.
    Picard S; Lacroix P
    Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels].
    Nakaya H
    Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):384-92. PubMed ID: 12835532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in infants and young children.
    Antzelevitch C
    J Electrocardiol; 2001; 34 Suppl():177-81. PubMed ID: 11781953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG.
    Hayashi K; Shimizu M; Ino H; Yamaguchi M; Terai H; Hoshi N; Higashida H; Terashima N; Uno Y; Kanaya H; Mabuchi H
    Clin Sci (Lond); 2004 Aug; 107(2):175-82. PubMed ID: 15043509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
    Zünkler BJ
    Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of acquired long QT syndrome.
    Roden DM; Viswanathan PC
    J Clin Invest; 2005 Aug; 115(8):2025-32. PubMed ID: 16075043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
    Briasoulis A; Agarwal V; Pierce WJ
    Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug induced QT prolongation].
    Altmann D; Eggmann U; Ammann P
    Wien Klin Wochenschr; 2008; 120(5-6):128-35. PubMed ID: 18365152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long QT syndromes: genetic basis and clinical implications.
    Chiang CE; Roden DM
    J Am Coll Cardiol; 2000 Jul; 36(1):1-12. PubMed ID: 10898405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death.
    Vincent GM
    Annu Rev Med; 1998; 49():263-74. PubMed ID: 9509262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.